questions on the origin aetiology point for these disorders, largely thought to arise from defective placentation in the first trimester.
Objectives:
To compare the performance of screening for pre-eclampsia (PE) based on risk factors from the medical history, as recommended by NICE and ACOG, with the method proposed by the Fetal Medicine Foundation (FMF), which uses Bayes theorem to combine the a priori risk from maternal factors, derived by a multivariable logistic model, with the results of various combinations of biophysical and biochemical measurements. Methods: This was a prospective European multicentre study of screening for PE in 8,775 singleton pregnancies at 11-13 weeks' gestation in 12 hospitals. A previously published FMF algorithm was used for the calculation of patient-specific risk of PE in each patient. The detection rates (DR) and false positive rates (FPR) for delivery with PE at <32, <37 and >37 weeks were estimated and compared to those derived from application of NICE guidelines and ACOG recommendations. Results: In the study population there were 239 (2.7%) cases that developed PE, including 17 (0.2%), 59 (0.7%) and 180 (2.0%) at <32, <37 and >37 weeks, respectively. Screening with use of the FMF algorithm and the combination of maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UTPI) and serum placental growth factor (PLGF) detected 100% (95% CI 80-100) for PE at <32 weeks, 75% (95% CI 62-85) for PE at <37 weeks and 43% (95% CI 35-50) for PE at >37 weeks, at 10.0% FPR. Screening with use of NICE guidelines detected 41% (95% CI 18-67) for PE at <32 weeks, 39% (95% CI 27-53) for PE at <37 weeks and 34% (95% CI 27-41) for PE at >37 weeks, at 10.3% FPR. Screening with use of ACOG recommendations detected 94% (95% CI 71-100) for PE at <32 weeks, 90% (95% CI 79-96) for PE at <37 weeks and 89% (95% CI 84-94) for PE at >37 weeks, at 64.3% FPR. Conclusions: Performance of screening for PE at 11-13 weeks' gestation by the FMF algorithm and combination of maternal factors, MAP, UTPI and PLGF is by far superior to the methods recommended by NICE and ACOG. Objectives: To evaluate the discriminative capacity of uterine artery pulsatility index (UtA-PI) in the identification of women remaining at high risk of pre-eclampsia (PE) after first trimester initiation of aspirin. Methods: We conducted a post-hoc analysis of data from a clinical randomised controlled trial of women with prior PE singleton fetus randomised to either 80 mg or 160 mg at bedtime from 10-14 weeks and followed until delivery. A follow-up visit was planned at 16-18 weeks for measurement of mean arterial blood pressure (MAP), UtA-PI and PFA-100 to evaluate aspirin non-responsiveness (PFA-100<145). Mean difference and ROC curves analyses with area under the curve (AUC), detection rate (DR) and false-positive rates (FPR) were used. Results: We observed 14 cases (13%) of PE and 3 (3%) cases of preterm PE out of 106 women with complete follow-up. UtA-PI at 16-18 weeks was discriminative of participants who developed preterm PE (AUC: 0.89; 95%CI: 0.77-1.00) but, not for those who developed term PE (AUC: 0.50; 95%CI: 0.32-0.69). Regarding aspirin resistance, participants who developed PE had a lower PFA-100 (mean difference: 50; 95%CI: 21-79, p=0.001) but the power was insufficient for preterm PE (only 3 cases; mean difference: 37; 95%CI: -48-122, p=0.39).
Taking into account aspirin resistance, UtA-PI and MAP, we could identify 62% of PE (at FPR=15%) and 100% of preterm PE (at FPR=6%) at 16-18 weeks. Conclusions: UtA-PI at 16-18 weeks is discriminative of women who will develop preterm PE but not term PE. All women who will develop preterm PE and most of those who will develop term PE despite initiation of aspirin in the first trimester could be identify by the combination of UtA-PI, MAP, and PFA-100 measured at 16-18 weeks. 
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